EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, ...

The primary logo features the fan-favorite bear with the rolling Smoky Mountains. The Smokies script sits on top of the ...

AI-enhanced manufacturing applications are now being deployed around the world as a massive upgrade in efficiency.

The company has made significant progress in its pipeline, with 11 positive Phase III readouts and plans for five major new product approvals next year. GSK PLC (NYSE:GSK) successfully resolved ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

New approvals and data in vaccines should see growth return after the current headwinds have been navigated.” It comes after GSK struck a landmark 2.2 billion US dollar (£1.68 billion) settlement to ...

“Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, ” said Emma Walmsley, CEO. Guidance: GSK reaffirms ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...